Zelo

Zelo Therapeutics is a private biotechnology company focused on the discovery and development of novel, non-opioid therapies for the treatment of chronic and acute pain. The company leverages its expertise in ion channel pharmacology to develop highly selective small molecule inhibitors targeting specific sodium channels, such as Nav1.7 and Nav1.8, which are validated targets for pain signaling. By focusing on peripheral targets, Zelo aims to provide effective pain relief while avoiding the central nervous system side effects and addiction potential associated with traditional opioid treatments. The company's lead programs are currently in the pre-clinical stage, with a focus on optimizing candidates for clinical entry.